Canonical and noncanonical Wnt pathway: A comparison among normal ovary, benign ovarian tumor and ovarian cancer

Oncology Reports

Volumn 21, Issue 2, 2009, Pages 313-320

  Filho, Levon Badiglian ^a   Oshima, Celina Tizuko Fujiyama ^a   Lima, Flávio de Oliveira ^a   Costa, Henrique de Oliveira ^a   Damaão, Robério de Sousa ^a   Gomes, Thiago Simão ^a   Gonçalves, Wagner José ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

catenin; Frizzled; Ovarian cancer; Wnt; Wnt5a

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; PROTEIN FZD1; PROTEIN FZD5; UNCLASSIFIED DRUG; WNT PROTEIN; WNT1 PROTEIN; WNT5A PROTEIN; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CANCER PATIENT; CANONICAL ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE SECTION; BIOSYNTHESIS; CANCER STAGING; COMPARATIVE STUDY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NEOPLASM; OVARY; PATHOLOGY; PHYSIOLOGY;

BETA CATENIN; FEMALE; FRIZZLED RECEPTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS;

EID: 62849100998     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000223     Document Type: Article

References (48)

1. Boerboom D, Paquet M, Hsieh M, Liu J, Jamin SP, Behringer RR, Sirois J, Taketo MM and Richards JS: Misregulated Wnt/beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res 65: 9206-9215, 2005.
2. Nusse R, Brown A, Papkoff J, Scambler P, Shackleford G, McMahon A, Moon R and Varmus H: A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 64: 231-232, 1991.
3. McMahon JA and McMahon AP: Nucleotide sequence, chromosomal localization and developmental expression of the mouse int-1-related gene. Development 107: 643-650, 1989.
4. Nusse R and Varmus HE: Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31: 99-109, 1982.
5. Van Ooyen A and Nusse R: Structure and nucleotide sequence of the putative mammary oncogene int-1; proviral insertions leave the protein-encoding domain intact. Cell 39: 233-240, 1984.
6. Johnson ML and Rajamannan N: Diseases of Wnt signaling. Rev Endocr Metab Disord 7: 41-9, 2006. Erratum in: Rev Endocr Metab Disord 8: 183, 2007.
7. Habas R and Dawid IB: Dishevelled and Wnt signaling: is the nucleus the final frontier? J Biol 4: 2, 2005.
8. Chen AE, Ginty DD and Fan CM: Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 433: 317-322, 2005.
9. Sarkar L and Sharpe PT: Expression of Wnt signalling pathway genes during tooth development. Mech Dev 85: 197-200, 1999.
10. Iozzo RV, Eichstetter I and Danielson KG: Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res 55: 3495-3499, 1995.
11. Danielson KG, Pillarisetti J, Cohen IR, Sholehvar B, Huebner K, Ng LJ, Nicholls JM, Cheah KS and Iozzo RV: Characterization of the complete genomic structure of the human WNT-5A gene, functional analysis of its promoter, chromosomal mapping, and expression in early human embryogenesis. J Biol Chem 270: 31225-31234, 1995.
12. Hollyday M, McMahon JA and McMahon AP: Wnt expression patterns in chick embryo nervous system. Mech Dev 52: 9-25, 1995.
13. Yamaguchi TP, Bradley A, McMahon AP and Jones S: A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126: 1211-1223, 1999.
14. Olson DJ, Gibo DM, Saggers G, Debinski W and Kumar R: Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. Cell Growth Differ 8: 417-423, 1997.
15. Kremenevskaja N, von Wasielewski R, Rao AS, Schöfl C, Andersson T and Brabant G: Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144-2154, 2005.
16. Jonsson M, Dejmek J, Bendahl PO and Andersson T: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62: 409-416, 2002.
17. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J and Matsumoto K: The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23: 131-139, 2003.
18. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ and Yang Y: Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162: 899-908, 2003.
19. Ricken A, Lochhead P, Kontogiannea M and Farookhi R: Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology 143: 2741-2749, 2002.
20. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576, 1996.
21. Milovanovic T, Planutis K, Nguyen A, Marsh JL, Lin F, Hope C and Holcombe RF: Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 25: 1337-1342, 2004.
22. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T and Truong T: Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55: 220-226, 2002.
23. Zilberberg A, Yaniv A and Gazit A: The low density lipoprotein receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and down-regulates the canonical Wnt signaling pathway. J Biol Chem 279: 17535-17542, 2004.
24. GeneCards (http://genome-www.stanford.edu/cgi-bin/genecards/ carddisp.pl?gene=FZD1&search=Frizzled&suff=txt).
25. Pukrop T and Binder C: The complex pathways of Wnt 5a in cancer progression. J Mol Med 86: 259-266, 2008.
26. Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O'Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, Butzow R, Weber BL and Coukos G: Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 66: 4627-4635, 2006.
27. Weichert W, Gekeler V, Denkert C, Dietel M and Hauptmann S: Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. Int J Oncol 23: 633-639, 2003.
28. D'Souza T, Indig FE and Morin PJ: Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells. Exp Cell Res 313: 3364-3375, 2007.
29. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M and Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279-288, 2002.
30. Jönsson M, Smith K and Harris AL: Regulation of Wnt5a expression in human mammary cells by protein kinase C activity and the cytoskeleton. Br J Cancer 78: 430-438, 1998.
31. D'Souza T, Agarwal R and Morin PJ: Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem 280: 26233-26240, 2005.
32. Mikels AJ and Nusse R: Wnts as ligands: processing, secretion and reception. Oncogene 25: 7461-7468, 2006.
33. Mikels AJ and Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4: 115, 2006.
34. Gordon MD and Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281: 22429-22433, 2006.
35. Liu G, Bafico A and Aaronson SA: The mechanism of endogenous receptor activation functionally distinguishes canonical and noncanonical Wnts. Mol Cell Biol 25: 3475-3482, 2005.
36. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S, Trümper L and Binder C: Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci USA 103: 5454-5459, 2006.
37. Dejmek J, Dejmek A, Säfholm A, Sjölander A and Andersson T: Wnt-5a protein expression in primary Dukes' B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 65: 9142-9146, 2005.
38. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W and Kikuchi A: Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66: 10439-10448, 2006.
39. Yamamoto H, Yoo SK, Nishita M, Kikuchi A and Minami Y: Wnt5a modulates glycogen synthase kinase 3 to induce phosphorylation of receptor tyrosine kinase Ror2. Genes Cells 12: 1215-1223, 2007.
40. Rask K, Nilsson A, Brännström M, Carlsson P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 89: 1298-1304, 2003.
41. Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H, Zhou C, Zhang G, Quan L, Bai J and Xu N: Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours. Br J Cancer 94: 686-691, 2006.
42. Behrens J: The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans 33: 672-675, 2005.
43. Chou YY, Jeng YM, Kao HL, Chen T, Mao TL and Lin MC: Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology 43: 151-156, 2003.
44. Brembeck FH, Rosário M and Birchmeier W: Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 16: 51-59, 2006.
45. Davies BR, Worsley SD and Ponder BA: Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology 32: 69-80, 1998.
46. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 18: S19-S32, 2005.
47. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suárez A and Armas A: Beta-catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 155: 527-536, 1999.
48. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL and Rimm DL: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66: 5487-5494, 2006.